Nektar Therapeutics Stock Today
| NKTR Stock | USD 1.13 0.06 5.61% |
Performance0 of 100
| Odds Of DistressOver 80
|
Nektar Therapeutics is selling at 1.13 as of the 28th of November 2024; that is 5.61 percent up since the beginning of the trading day. The stock's lowest day price was 1.08. Nektar Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Nektar Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of May 1994 | Category Healthcare | Classification Health Care |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California. The company has 184.46 M outstanding shares of which 5.13 M shares are now shorted by private and institutional investors with about 3.91 trading days to cover. More on Nektar Therapeutics
Moving against Nektar Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Nektar Stock Highlights
| CEO and President and Director | Howard Robin | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Trump Equities (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Trump Equities, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsNektar Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Nektar Therapeutics' financial leverage. It provides some insight into what part of Nektar Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nektar Therapeutics (NKTR) is traded on NASDAQ Exchange in USA. It is located in 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158 and employs 137 people. Nektar Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 197.37 M. Nektar Therapeutics conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 184.46 M outstanding shares of which 5.13 M shares are now shorted by private and institutional investors with about 3.91 trading days to cover.
Nektar Therapeutics currently holds about 546.39 M in cash with (192.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.91, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Nektar Therapeutics Probability Of Bankruptcy
Ownership AllocationNektar Therapeutics maintains a total of 184.46 Million outstanding shares. The majority of Nektar Therapeutics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Nektar Therapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Nektar Therapeutics. Please pay attention to any change in the institutional holdings of Nektar Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Nektar Ownership Details
Nektar Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Renaissance Technologies Corp | 2024-09-30 | 3.3 M | |
| State Street Corp | 2024-06-30 | 3 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.9 M | |
| Jacobs Levy Equity Management, Inc. | 2024-09-30 | 2.8 M | |
| Monaco Asset Management | 2024-09-30 | 2 M | |
| Shay Capital Llc | 2024-06-30 | 1.8 M | |
| Two Sigma Advisers, Llc | 2024-06-30 | 1.8 M | |
| Goldman Sachs Group Inc | 2024-06-30 | 1.8 M | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 1.5 M | |
| Deep Track Capital, Lp | 2024-09-30 | 15.9 M | |
| Blackrock Inc | 2024-06-30 | 15.2 M |
Nektar Therapeutics Historical Income Statement
Nektar Stock Against Markets
Nektar Therapeutics Corporate Management
| Mark JD | Chief VP | Profile | |
| Mark Wilson | Chief Sec | Profile | |
| Sandra Gardiner | Interim Officer | Profile | |
| Kevin Brodbeck | VP Operations | Profile |
Additional Tools for Nektar Stock Analysis
When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.